Amplo Biotechnology, Inc.
Towson, MD · Founded 2019 · CIK 0001886216 · Biotech · Private
AAV gene therapy vectors carrying therapeutic genes for neuromuscular junction disorders, initially AMP-201 (AAV8-ColQ) for Congenital Myasthenic Syndromes
amplobiotechnology.com →- Grants
- $7.7M
- 8 awards
- Sector median: 1
- Raised
- $2.2M
- 1 Form D · Oct 2021
- 60 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Targeted DOK7 gene therapy for Congenital Myasthenic Syndromes | $253,925 | |
| Private capital raised | Form D · SEC | $2,235,701 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeted DOK7 gene therapy for Congenital Myasthenic Syndromes | $1,602,833 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeted DOK7 gene therapy for Congenital Myasthenic Syndromes | $144,102 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeted ColQ gene therapy for Congenital Myasthenic Syndromes | $493,111 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeted ColQ gene therapy for Congenital Myasthenic Syndromes | $207,090 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeted DOK7 gene therapy for Congenital Myasthenic Syndromes | $2,999,358 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeted ColQ gene therapy for Congenital Myasthenic Syndromes | $601,044 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeted ColQ gene therapy for Congenital Myasthenic Syndromes | $1,357,367 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2545 | Neela Therapeutics, Inc. | — | $12M |
| 2546 | Regenerate, Inc. | — | $2.3M |
| 2547 | ANAGIN | — | $2.3M |
| 2548 | Amplo Biotechnology, Inc. | — | $2.2M |
| 2549 | Mira Dx, Inc. | — | $2.1M |
| 2550 | CellVax Therapeutics, Inc. | — | $2.1M |
| 2551 | BACTRIA PHARMACEUTICALS LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Daniel BradburyDirector
- Paul HawkinsDirector · Executive Officer
- Jean KimDirector
- Matthew PaulsDirector
- Patricio SepulvedaDirector · Executive Officer
- Terry VanceDirector
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.